These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35531468)

  • 1. Course of Hyperkalemia in Patients on Hemodialysis.
    Spinowitz B; Fishbane S; Fukagawa M; Ford M; Guzman N; Rastogi A
    Int J Nephrol; 2022; 2022():6304571. PubMed ID: 35531468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
    Ni Z; Lu R; Xu X; Bian X; Zhou Z; Yang J; Luo Q; Chen M; Chen C; Sun X; Yu L; He Q; Jiang H; Yuan W; Li Y; Zhou R; Wang J; Zhang X; Zuo L; Meng X; Chang Z; Zhao J; Wessman P; Xiang P;
    Clin Ther; 2023 Jul; 45(7):633-642. PubMed ID: 37385905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    BMC Nephrol; 2022 Feb; 23(1):59. PubMed ID: 35135481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study.
    Fishbane S; Jadoul M; Dember L; Kovesdy CP; Al-Shurbaji A; Lisovskaja V; Sekar P; Katona B; Guzman N; Herzog C
    BMJ Open; 2023 May; 13(5):e071309. PubMed ID: 37230521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
    Peacock WF; Rafique Z; Vishnevskiy K; Michelson E; Vishneva E; Zvereva T; Nahra R; Li D; Miller J
    Acad Emerg Med; 2020 Jun; 27(6):475-486. PubMed ID: 32149451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
    Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
    Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperkalaemia prevalence and dialysis patterns in Chinese patients on haemodialysis: an interim analysis of a prospective cohort study (PRECEDE-K).
    Ni Z; Jin H; Lu R; Zhang L; Yao L; Shao G; Zuo L; Qin S; Zhang X; Zhang Q; Yu W; Luo Q; Ren Y; Peng H; Xiao J; Yang Q; Chen Q; Shi Y;
    BMC Nephrol; 2023 Aug; 24(1):233. PubMed ID: 37559023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.
    Anker SD; Kosiborod M; Zannad F; Piña IL; McCullough PA; Filippatos G; van der Meer P; Ponikowski P; Rasmussen HS; Lavin PT; Singh B; Yang A; Deedwania P
    Eur J Heart Fail; 2015 Oct; 17(10):1050-6. PubMed ID: 26011677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.
    Kaisar MO; Wiggins KJ; Sturtevant JM; Hawley CM; Campbell SB; Isbel NM; Mudge DW; Bofinger A; Petrie JJ; Johnson DW
    Am J Kidney Dis; 2006 May; 47(5):809-14. PubMed ID: 16632019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium zirconium cyclosilicate in hyperkalemia.
    Packham DK; Rasmussen HS; Lavin PT; El-Shahawy MA; Roger SD; Block G; Qunibi W; Pergola P; Singh B
    N Engl J Med; 2015 Jan; 372(3):222-31. PubMed ID: 25415807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Potassium and Mortality Risk in Hemodialysis Patients: A Cohort Study.
    de Rooij ENM; Dekker FW; Le Cessie S; Hoorn EJ; de Fijter JW; Hoogeveen EK;
    Kidney Med; 2022 Jan; 4(1):100379. PubMed ID: 35072043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, recurrence and seasonal variation of hyperkalemia among patients on hemodialysis.
    Tsiagka D; Georgianos PI; Pikilidou MI; Vaios V; Roumeliotis S; Syrganis C; Mavromatidis K; Metallidis S; Liakopoulos V; Zebekakis PE
    Int Urol Nephrol; 2022 Sep; 54(9):2327-2334. PubMed ID: 35133576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter study of hemodialysis using individualized dialysate potassium concentrations.
    He H; Wu J; Lu W; Wu H; Zhu R; Yu G; Jiang G; Wang N; Guo Z; Deng Y; Xu X
    Ann Palliat Med; 2021 Dec; 10(12):12218-12229. PubMed ID: 35016414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Short-term effect of sodium zirconium cyclosilicate on potassium lowering in chronic kidney disease patients with hyperkalemia].
    Bai C; Shang J; Kang D; Yu W; Zhang FL; Zhang WF; Wu F; Guo RX; Zhang YD; Zhao ZZ
    Zhonghua Yi Xue Za Zhi; 2020 Oct; 100(38):2997-3000. PubMed ID: 33086450
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.
    Zannad F; Hsu BG; Maeda Y; Shin SK; Vishneva EM; Rensfeldt M; Eklund S; Zhao J
    ESC Heart Fail; 2020 Feb; 7(1):54-64. PubMed ID: 31944628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of zinc supplementation on serum zinc and cholesterol concentrations in hemodialysis patients.
    Chevalier CA; Liepa G; Murphy MD; Suneson J; Vanbeber AD; Gorman MA; Cochran C
    J Ren Nutr; 2002 Jul; 12(3):183-9. PubMed ID: 12105816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.